Browsing by Author "Ayandipo, O."

Now showing 1 - 3 of 3

Nigerian surgical outcomes – Report of a 7-day prospective cohort study and external validation of the African surgical outcomes study surgical risk calculator
(Elsevier Ltd., 2019) Osinaike, B.; Ayandipo, O.; Onyeka, T.; Alagbe-Briggs, O.; Mohammed, A.; Oyedepo, O.; Nuhu, A.; Asudoh, F.; Akanmu, O.; Nwokorie, C.; Mohammed, A.; Edubiol, M.; Izuoram, K.; Mohammed, R.; Nweze, O.; Efu, M.; Eguma, S.; Jasper, A.; Ewah, R.; Akhideno, I.; Nnaji, C.; Adov, S.; Ogboli-Nwasor, E.; Atiku, M.; Salisu, I.; Adinoyi, Y.|; Aguz, E.; Desalu, I.; Samuel, L.; Olorode, Y.; Fatungase, O.; Akinwonmia, O.; Faponle, F.; Idowu, O.; Isamade, E.; Aliyu, A.; Buba, S.; Hamza, G.; Onajin-Obembe, B.; Amanor-Boadu, S.
Background: Surgical outcomes study for individual nations remains important because of international differences in patterns of surgical disease. We aimed to contribute to data on post-operative complications, critical care admissions and mortality following elective surgery in Nigeria and also validate the African Surgical Outcomes Study (ASOS) surgical risk calculator in our adult patient cohort. Materials and methods: We conducted a 7-day, national prospective observational cohort study in consented consecutive patients undergoing elective surgery with a planned overnight hospital stay following elective surgery during a seven-day study period. The outcome measures were in-hospital postoperative complications, critical care admissions and in-hospital mortality censored at 30 days. Also, we identified variables which significantly contributed to higher ASOS surgical risk score. External validation was performed using area under the receiver operating characteristic curve (ROC) for discrimination assessment and Hosmer–Lemeshow test for calibration. Results: A total of 1,425 patients from 79 hospitals participated in the study. Postoperative complications occurred in 264(18.5%, 95% CI 16.6–20.6), 20(7.6%) of whom were admitted into the ICU and 16(6.0%) did not survive. Total ICU admission was 57 (4%), with mortality rate of 23.5% following planned admission and overall in-hospital death was 22(1.5%, 95% CI 0.9–2.2). All prognostic factors in the ASOS risk calculator were significantly associated with higher ASOS score and the scoring system showed moderate discrimination (0⋅73, 95% CI 0.62–0.83). Hosmer–Lemeshow χ2 test revealed scale was well calibrated in the validation cohort. Conclusion: NiSOS validates the findings of ASOS and the ability of the ASOS surgical risk calculator to predict risk of developing severe postoperative complications and mortality. We identified failure-to-rescue as a problem in Nigeria. Furthermore, this study has provided policy makers with benchmarks that can be used to monitor programmes aimed at reducing the morbidity and mortality after elective surgery. We recommend the adoption of the ASOS surgical risk calculator as a tool for risk stratification preoperatively for elective surgery.
The african female Breast Cancer Epidemiology study protocol
(Frontiers Media, 2022-04) Ezeome, E. R.; Yawe, K.-D. T.; Ayandipo, O.; Badejo, O.; Adebamowo, S. N.; Achusi, B.; Fowotade, A.; Ogun, G.; Adebamowo, C. A.
Breast cancer is now the commonest cancer in most sub-Saharan African countries. Few studies of the epidemiology and genomics of breast cancer and its molecular subtypes in these countries have been done. The African Female Breast Cancer Epidemiology (AFBRECANE) study, a part of the Human Heredity and Health in Africa (H3Africa) initiative, is designed to study the genomics and epidemiology of breast cancer and its molecular subtypes in Nigerian women. We link recruitment of breast cancer cases at study sites with population-based cancer registries activities to enable ascertainment of the incidence of breast cancer and its molecular subtypes. We use centralized laboratory processing to characterize the histopathological and molecular diagnosis of breast cancer and its subtypes using multiple technologies. By combining genome-wide association study (GWAS) data from this study with that generated from 12,000 women participating in our prospective cohort study of cervical cancer, we conduct GWAS of breast cancer in an entirely indigenous African population. We test associations between dietary intakes and breast cancer and focus on vitamin D which we measure using dietary intakes, serum vitamin D, and Mendelian randomization. This paper describes the AFBRECANE project, its design, objectives and anticipated contributions to knowledge and understanding of breast cancer.
The african female Breast Cancer Epidemiology study protocol
(Frontiers Media, 2022-04) Ezeome, E. R.; Yawe, K.-D. T.; Ayandipo, O.; Badejo, O.; Adebamowo, S. N.; Achusi, B.; Fowotade, A.; Ogun, G.; Adebamowo, C. A.
Breast cancer is now the commonest cancer in most sub-Saharan African countries. Few studies of the epidemiology and genomics of breast cancer and its molecular subtypes in these countries have been done. The African Female Breast Cancer Epidemiology (AFBRECANE) study, a part of the Human Heredity and Health in Africa (H3Africa) initiative, is designed to study the genomics and epidemiology of breast cancer and its molecular subtypes in Nigerian women. We link recruitment of breast cancer cases at study sites with population-based cancer registries activities to enable ascertainment of the incidence of breast cancer and its molecular subtypes. We use centralized laboratory processing to characterize the histopathological and molecular diagnosis of breast cancer and its subtypes using multiple technologies. By combining genome-wide association study (GWAS) data from this study with that generated from 12,000 women participating in our prospective cohort study of cervical cancer, we conduct GWAS of breast cancer in an entirely indigenous African population. We test associations between dietary intakes and breast cancer and focus on vitamin D which we measure using dietary intakes, serum vitamin D, and Mendelian randomization. This paper describes the AFBRECANE project, its design, objectives and anticipated contributions to knowledge and understanding of breast cancer.